{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:12:30Z","timestamp":1771049550932,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"DOI":"10.7759\/cureus.103569","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:36:00Z","timestamp":1771047360000},"source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Epithelial Ovarian Cancer Surveillance Protocols"],"prefix":"10.7759","author":[{"given":"Divya  P","family":"Vuppu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Bhati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranidhashree C","family":"A","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheejamol","family":"V S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre LA","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, et al.. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018, 68:284-96. 10.3322\/caac.21456","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: what is the best management?","volume":"9","author":"Garzon S","year":"2020","unstructured":"Garzon S, Lagan\u00e0 AS, Casarin J, et al.. Secondary and tertiary ovarian cancer recurrence: what is the best management?. Gland Surg. 2020, 9:1118-29. 10.21037\/gs-20-325","journal-title":"Gland Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34002","article-title":"Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020","volume":"151","author":"Cabasag CJ","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J, et al.. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022, 151:1535-41. 10.1002\/ijc.34002","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.61622\/rbgo\/2025FPS3","article-title":"Follow-up of women after gynecological cancer treatment","volume":"47","author":"da Silva AL","year":"2025","unstructured":"da Silva AL, Pra\u00e7a MS, Pinhati ME, Castro LG, Moretti-Marques R, Nogueira-Rodrigues A, C\u00e2ndido EB. Follow-up of women after gynecological cancer treatment. Rev Bras Ginecol Obstet. 2025, 47:0. 10.61622\/rbgo\/2025FPS3","journal-title":"Rev Bras Ginecol Obstet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002885","article-title":"Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study","volume":"32","author":"Feinberg J","year":"2022","unstructured":"Feinberg J, Carthew K, Webster E, et al.. Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. Int J Gynecol Cancer. 2022, 32:159-64. 10.1136\/ijgc-2021-002885","journal-title":"Int J Gynecol Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2013.14.12.7193","article-title":"Detection of recurrence in a surveillance program for epithelial ovarian cancer","volume":"14","author":"Suprasert P","year":"2013","unstructured":"Suprasert P, Chalapati W. Detection of recurrence in a surveillance program for epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013, 14:7193-6. 10.7314\/apjcp.2013.14.12.7193","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard I","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al.. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019, 381:2416-28. 10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194621","article-title":"Targeting homologous recombination deficiency in ovarian cancer with PARP inhibitors: synthetic lethal strategies that impact overall survival","volume":"14","author":"Xie T","year":"2022","unstructured":"Xie T, Dickson KA, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ. Targeting homologous recombination deficiency in ovarian cancer with PARP inhibitors: synthetic lethal strategies that impact overall survival. Cancers (Basel). 2022, 14:4621. 10.3390\/cancers14194621","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181a1cc02","article-title":"Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study","volume":"19","author":"Gadducci A","year":"2009","unstructured":"Gadducci A, Fuso L, Cosio S, et al.. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009, 19:367-74. 10.1111\/IGC.0b013e3181a1cc02","journal-title":"Int J Gynecol Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100595","article-title":"The role of asymptomatic screening in the detection of recurrent ovarian cancer","volume":"33","author":"Richardson MT","year":"2020","unstructured":"Richardson MT, Routson S, Karam A, Dorigo O, Levy K, Renz M, Diver EJ. The role of asymptomatic screening in the detection of recurrent ovarian cancer. Gynecol Oncol Rep. 2020, 33:100595. 10.1016\/j.gore.2020.100595","journal-title":"Gynecol Oncol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003506","article-title":"The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care","volume":"32","author":"Janke MJ","year":"2022","unstructured":"Janke MJ, Santiago S, Straubhar AM, Uppal S. The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care. Int J Gynecol Cancer. 2022, 32:913-7. 10.1136\/ijgc-2022-003506","journal-title":"Int J Gynecol Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.09.017","article-title":"Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer","volume":"131","author":"Armstrong A","year":"2013","unstructured":"Armstrong A, Otvos B, Singh S, Debernardo R. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2013, 131:503-7. 10.1016\/j.ygyno.2013.09.017","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1037_23","article-title":"Cancer care and economic burden - a narrative review","volume":"12","author":"Muralidharan S","year":"2023","unstructured":"Muralidharan S, Gore M, Katkuri S. Cancer care and economic burden - a narrative review. J Family Med Prim Care. 2023, 12:3042-7. 10.4103\/jfmpc.jfmpc_1037_23","journal-title":"J Family Med Prim Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12961-021-00732-y","article-title":"The household financial burden of non-communicable diseases in low- and middle-income countries: a systematic review","volume":"19","author":"Kazibwe J","year":"2021","unstructured":"Kazibwe J, Tran PB, Annerstedt KS. The household financial burden of non-communicable diseases in low- and middle-income countries: a systematic review. Health Res Policy Syst. 2021, 19:96. 10.1186\/s12961-021-00732-y","journal-title":"Health Res Policy Syst"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1065737","article-title":"Financial toxicity of cancer treatment in India: towards closing the cancer care gap","volume":"11","author":"Prinja S","year":"2023","unstructured":"Prinja S, Dixit J, Gupta N, et al.. Financial toxicity of cancer treatment in India: towards closing the cancer care gap. Front Public Health. 2023, 11:1065737. 10.3389\/fpubh.2023.1065737","journal-title":"Front Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2021.22.3.671","article-title":"Out-of-pocket, catastrophic health expenditure and distress financing on non-communicable diseases in India: a systematic review with meta-analysis","volume":"22","author":"Dhankhar A","year":"2021","unstructured":"Dhankhar A, Kumari R, Bahurupi YA. Out-of-pocket, catastrophic health expenditure and distress financing on non-communicable diseases in India: a systematic review with meta-analysis. Asian Pac J Cancer Prev. 2021, 22:671-80. 10.31557\/APJCP.2021.22.3.671","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196106","article-title":"Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: do Indian households face distress health financing?","volume":"13","author":"Kastor A","year":"2018","unstructured":"Kastor A, Mohanty SK. Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: do Indian households face distress health financing?. PLoS One. 2018, 13:e0196106. 10.1371\/journal.pone.0196106","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2021.22.12.3755","article-title":"Economic burden of cancer treatment in a region in South India: a cross sectional analytical study","volume":"22","author":"Maurya PK","year":"2021","unstructured":"Maurya PK, Murali S, Jayaseelan V, Thulasingam M, Pandjatcharam J. Economic burden of cancer treatment in a region in South India: a cross sectional analytical study. Asian Pac J Cancer Prev. 2021, 22:3755-62. 10.31557\/APJCP.2021.22.12.3755","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001040","article-title":"Outcomes and cost analysis of surveillance strategies after initial treatment for women with recurrent ovarian cancer","volume":"27","author":"Alexander VM","year":"2017","unstructured":"Alexander VM, Gordon AN, Howard DH, Khanna N. Outcomes and cost analysis of surveillance strategies after initial treatment for women with recurrent ovarian cancer. Int J Gynecol Cancer. 2017, 27:1333-42. 10.1097\/IGC.0000000000001040","journal-title":"Int J Gynecol Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006119.pub3","article-title":"Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment","volume":"2014","author":"Clarke T","year":"2014","unstructured":"Clarke T, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev. 2014, 2014:CD006119. 10.1002\/14651858.CD006119.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2023.102487","article-title":"Fear of recurrence in women with ovarian cancer: a qualitative evidence synthesis","volume":"68","author":"Nic Giolla Chomhaill C","year":"2024","unstructured":"Nic Giolla Chomhaill C, Ward J, Dowling M. Fear of recurrence in women with ovarian cancer: a qualitative evidence synthesis. Eur J Oncol Nurs. 2024, 68:102487. 10.1016\/j.ejon.2023.102487","journal-title":"Eur J Oncol Nurs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31827f37b0","article-title":"Life after gynecologic cancer -- a review of patients quality of life, needs, and preferences in regard to follow-up","volume":"23","author":"Dahl L","year":"2013","unstructured":"Dahl L, Wittrup I, V\u00e6ggemose U, Petersen LK, Blaakaer J. Life after gynecologic cancer -- a review of patients quality of life, needs, and preferences in regard to follow-up. Int J Gynecol Cancer. 2013, 23:227-34. 10.1097\/IGC.0b013e31827f37b0","journal-title":"Int J Gynecol Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445546-rethinking-epithelial-ovarian-cancer-surveillance-protocols","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:36:01Z","timestamp":1771047361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445546-rethinking-epithelial-ovarian-cancer-surveillance-protocols"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.103569","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}